CN114515330A - 一种超微粉益母生化散及其制备方法 - Google Patents
一种超微粉益母生化散及其制备方法 Download PDFInfo
- Publication number
- CN114515330A CN114515330A CN202210039273.1A CN202210039273A CN114515330A CN 114515330 A CN114515330 A CN 114515330A CN 202210039273 A CN202210039273 A CN 202210039273A CN 114515330 A CN114515330 A CN 114515330A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- biochemical
- motherwort
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 49
- 241000207925 Leonurus Species 0.000 title claims abstract description 44
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 title claims abstract description 34
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 238000001035 drying Methods 0.000 claims abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 10
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 10
- 235000008397 ginger Nutrition 0.000 claims abstract description 10
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 9
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 235000011477 liquorice Nutrition 0.000 claims abstract description 9
- 238000004140 cleaning Methods 0.000 claims abstract description 7
- 230000001007 puffing effect Effects 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 7
- 244000273928 Zingiber officinale Species 0.000 claims abstract 3
- 238000000227 grinding Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000007602 hot air drying Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 24
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000001976 improved effect Effects 0.000 abstract description 3
- 208000037805 labour Diseases 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 244000144972 livestock Species 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004145 Endometritis Diseases 0.000 description 3
- 208000012287 Prolapse Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000021129 Postpartum disease Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000029785 Puerperal disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种超微粉益母生化散及其制备方法，属于中药技术领域，由以下重量份的原料组成：益母草40‑50份、当归15‑25份、川芎8‑13份、桃仁8‑13份、干姜5‑9份、甘草4‑8份。按照重量份称取各原料后洗净晾干；将原料干燥、膨化；初粉碎后；进行超微粉碎即得。本发明的超微粉益母生化散改善了药物的适口性；药物的破壁率高，使有效成分能充分释放，提高了生物利用率，避免药物浪费。能够有效解决禽畜产后恶露不行难题；能够有效提高机体免疫力和抗病能力，防治产后期疾病。制备工艺简单，实现了中药散剂质量标准可控、适于大规模工业化生产的目的。
Description
技术领域
本发明涉及中药技术领域，特别是涉及一种超微粉益母生化散及其制备方法。
背景技术
中药超微粉是指先进的超微粉碎技术与传统中药理论相结合，将中药材微粉化，该技术改善了中药的品质，提高了中药的利用率，推动了中药的标准化，是中药现代化的重要途径之一。中药超微粉碎直接将中药材的细胞壁打碎，由于中药的药效成分绝大部分分布于细胞内和细胞间质，以细胞内为主，通过特殊机械在特定的环境条件下将细胞壁打碎，从而使细胞内的有效成分释放出来，这样得到的中药粉称为超微粉。中药材绝大部分是以植物药材为主，植物药材的有效成分主要贮存在细胞内，超微粉碎技术可打破植物药材的细胞壁，使细胞内的有效成分释放出来，从而提高药材的生物利用度
益母生化散具有清热解毒、消炎抗菌、活血调经的作用。祛瘀、养血行气、温经止痛。主治产后恶露不行，胎衣不下，血瘀，子宫垂脱，子宫复旧不全，子宫内膜炎，感染等病症。目前传统的益母生化散的生物利用率低，有效成分难以充分释放，造成药物浪费。
发明内容
本发明的目的是提供一种超微粉益母生化散及其制备方法，以解决上述现有技术存在的问题。
为实现上述目的，本发明提供了如下方案：
本发明提供一种超微粉益母生化散，所述益母生化散由以下重量份的原料组成：益母草40-50份、当归15-25份、川芎8-13份、桃仁8-13份、干姜5-9份、甘草4-8份。
进一步的，所述益母生化散由以下重量份的原料组成：益母草45份、当归20份、川芎11份、桃仁11份、干姜7份、甘草6份。
本发明还提供上述超微粉益母生化散的制备方法，包括以下步骤：
(1)按照所述重量份称取各原料后洗净晾干；
(2)将所述步骤(1)的原料干燥、膨化；
(3)将所述步骤(2)膨化后的原料进行初粉碎；
(4)将所述步骤(3)初粉碎后进行超微粉碎即得。
进一步的，所述步骤(2)中干燥为热风干燥。
进一步的，所述步骤(2)中干燥是在40-70℃下干燥30-60min。
进一步的，所述干燥后各原料的含水量为8％-12％。
进一步的，所述步骤(2)中膨化是在1.5-4.0Mpa、135-160℃的条件下膨化45-90s。
进一步的，所述步骤(3)中初粉碎至粒度为70-90目。
进一步的，所述步骤(4)中超微粉碎可以是切式超微粉碎、撞式超微粉碎、磨式超微粉碎、气流粉碎。
进一步的，所述超微粉碎后粒径为15-30μm。
本发明与现有技术相比，具有以下技术效果：
益母草：活血调经、利尿消肿。具有兴奋子宫、增加冠状动脉流量、改善微循环、扩张外周血管及降低血压等作用，还有利尿及抑制皮肤真菌等作用。具有收缩子宫平滑肌的作用；能显著增加缺血性心肌冠脉流量及减慢心率；抗血小板聚集及抗血栓形成，增强机体细胞免疫功能。
当归：补血活血、调经止痛、润肠通便。有降低血小板聚集及抗血栓的功效与作用；促进造血系统功能；降血脂及抗动脉硬化；抗氧化和清除自由基；增强免疫系统功能；抑制I、Ⅱ、Ⅲ、Ⅳ型变态反应；对子宫具有兴奋及抑制的双向性作用；抑制前列腺增生；抗促性腺激素；抗辐射损伤；抗肿瘤；抗炎镇痛、抗损伤；保肝，利胆，促进消化，抑制胃肠的推动运动；具有抑制神经系统、松弛气管平滑肌、利尿、抑菌等作用。
川芎：活血行气，祛风止痛。对心脑血管系统的影响：对心脏有抑制作用；可扩血管，降血压；增加冠脉流量；对心肌及再灌注损伤有保护作用；改善微循环；改善脑循环及脑缺血。
桃仁：活血祛痰、润肠通便。具有抗凝血、抗直栓、改善血流、抗炎、镇痛和抗过敏等作用。
干姜：温中散寒、回阳通脉、燥湿消痰。具有镇静、镇痛、抗炎、升血压、抗凝血作用；对消化系统具有止吐、增强离体肠收缩等作用；灭螺，抗血吸虫，促进肾上腺皮质激素的合成与释放。
甘草：补脾益气、止咳祛痰、缓急定痛、调和药性。甘草有肾上腺皮质激素作用，抗炎、抗溃疡、抗过敏反应，抗癌，抗菌，抗病毒，促进胰液分泌，对离体肠有抑制，调节免疫功能，镇咳祛痰，抗突变，解毒，抗氧化，保护耳前庭功能、利尿，保肝、防止动脉硬化，抗脑缺血，预防糖尿病并发症等作用。
本发明运用了中药超微粉碎技术，使超微粉益母生化散的粒径可达15-30μm，粒径均匀，改善了药物的适口性；药物的破壁率高，使有效成分能充分释放，提高了生物利用率，避免药物浪费。能够有效解决禽畜产后恶露不行难题；能够有效提高机体免疫力和抗病能力，防治产后期疾病。
本发明超微粉益母生化散以超微粉全粉入药，中药原料能够全部充分利用，减少了药物服用量，节约中药材资源，最大限度地保留了药物成分，且保持了传统中药汤剂的效果，制备工艺简单，实现了中药散剂质量标准可控、适于大规模工业化生产的目的。
具体实施方式
现详细说明本发明的多种示例性实施方式，该详细说明不应认为是对本发明的限制，而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。
应理解本发明中所述的术语仅仅是为描述特别的实施方式，并非用于限制本发明。另外，对于本发明中的数值范围，应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明，否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料，但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入，用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时，以本说明书的内容为准。
在不背离本发明的范围或精神的情况下，可对本发明说明书的具体实施方式做多种改进和变化，这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见的。本申请说明书和实施例仅是示例性的。
关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等，均为开放性的用语，即意指包含但不限于。
实施例1
一种超微粉益母生化散，由以下重量份的原料组成：益母草40份、当归15份、川芎8份、桃仁8份、干姜5份、甘草4份。
实施例2
一种超微粉益母生化散，由以下重量份的原料组成：益母草50份、当归25份、川芎13份、桃仁13份、干姜9份、甘草8份。
实施例3
一种超微粉益母生化散，由以下重量份的原料组成：益母草45份、当归20份、川芎11份、桃仁11份、干姜7份、甘草6份。
实施例4
本发明实施例1所述超微粉益母生化散的制备方法，包括以下步骤：
(1)按照所述重量份称取各原料后洗净晾干；
(2)将所述步骤(1)的原料在40℃下热风干燥60min至含水量为12％，然后在1.5Mpa、135℃的条件下膨化90s；
(3)将所述步骤(2)膨化后的原料进行初粉碎至粒度为70目；
(4)将所述步骤(3)初粉碎后进行超微粉碎至30μm即得。
实施例5
本发明实施例2所述超微粉益母生化散的制备方法，包括以下步骤：
(1)按照所述重量份称取各原料后洗净晾干；
(2)将所述步骤(1)的原料在70℃下热风干燥30min至含水量为10％，然后在4.0Mpa、160℃的条件下膨化45s；
(3)将所述步骤(2)膨化后的原料进行初粉碎至粒度为80目；
(4)将所述步骤(3)初粉碎后进行超微粉碎至20μm即得。
实施例6
本发明实施例3所述超微粉益母生化散的制备方法，包括以下步骤：
(1)按照所述重量份称取各原料后洗净晾干；
(2)将所述步骤(1)的原料在60℃下热风干燥45min至含水量为8％，然后在3.0Mpa、150℃的条件下膨化60s；
(3)将所述步骤(2)膨化后的原料进行初粉碎至粒度为90目；
(4)将所述步骤(3)初粉碎后进行超微粉碎至15μm即得。
实施例7
一种超微粉益母生化散是由一下重量分的原料组成的：益母草43份、当归18份、川芎11份、桃仁10份、干姜7份、甘草5份。
其制备方法为：
(1)按照所述重量份称取各原料后洗净晾干；
(2)将所述步骤(1)的原料在55℃下热风干燥50min至含水量为9％，然后在2.5Mpa、145℃的条件下膨化75s；
(3)将所述步骤(2)膨化后的原料进行初粉碎至粒度为80目；
(4)将所述步骤(3)初粉碎后进行超微粉碎至18μm即得。
试验效果
下面以实施例3为例，说明相关动物试验效果
一、超微粉益母生化散治疗母猪产后疾病的临床效果
(1)临床病例：选自具有典型恶露不尽、胎衣不下、腹痛、子宫垂脱、子宫复旧不全、产后子宫内膜炎的患猪。
(2)试验方法：每只产后猪每次50g，开水冲调，候温灌服，每日一次，连用3天。从第1次给药后每天观察记录体温、呼吸、活动状态、精神、食欲、粪便、有无死亡等，连续观察7天。
(3)临床应用效果如表1所示。
表1超微粉益母生化散治疗母猪产后疾病的临床效果
| 病症 | 病例数/头 | 治愈数/头 | 无效数/头 | 治愈率/％ |
| 恶露不尽 | 60 | 58 | 1 | 96.67 |
| 胎衣不下 | 30 | 29 | 1 | 96.67 |
| 子宫垂脱 | 25 | 23 | 2 | 92.0 |
| 子宫复旧不全 | 15 | 14 | 1 | 93.33 |
由表1结果可知，实施例3的超微粉益母生化散对母畜产后恶露不尽、胎衣不下、血瘀腹痛、子宫垂脱、子宫复旧不全、产后子宫内膜炎等产后期疾病疗效显著。上述动物试验结果表明本发明的超微粉益母生化散制品用于产后恶露不行，血瘀腹痛预防治疗效果好、疗效显著，在防治母畜产后期疾病上疗效确实可靠。
以上所述的实施例仅是对本发明的优选方式进行描述，并非对本发明的范围进行限定，在不脱离本发明设计精神的前提下，本领域普通技术人员对本发明的技术方案做出的各种变形和改进，均应落入本发明权利要求书确定的保护范围内。
Claims (10)
1.一种超微粉益母生化散，其特征在于：所述益母生化散由以下重量份的原料组成：益母草40-50份、当归15-25份、川芎8-13份、桃仁8-13份、干姜5-9份、甘草4-8份。
2.根据权利要求1所述超微粉益母生化散，其特征在于：所述益母生化散由以下重量份的原料组成：益母草45份、当归20份、川芎11份、桃仁11份、干姜7份、甘草6份。
3.根据权利要求1-2任一项所述超微粉益母生化散的制备方法，其特征在于：所述制备方法包括以下步骤：
(1)按照所述重量份称取各原料后洗净晾干；
(2)将所述步骤(1)的原料干燥、膨化；
(3)将所述步骤(2)膨化后的原料进行初粉碎；
(4)将所述步骤(3)初粉碎后进行超微粉碎即得。
4.根据权利要求3所述超微粉益母生化散的制备方法，其特征在于：所述步骤(2)中干燥为热风干燥。
5.根据权利要求3所述超微粉益母生化散的制备方法，其特征在于：所述步骤(2)中干燥是在40-70℃下干燥30-60min。
6.根据权利要求4述超微粉益母生化散的制备方法，其特征在于：所述干燥后各原料的含水量为8％-12％。
7.根据权利要求3所述超微粉益母生化散的制备方法，其特征在于：所述步骤(2)中膨化是在1.5-4.0Mpa、135-160℃的条件下膨化45-90s。
8.根据权利要求3所述超微粉益母生化散的制备方法，其特征在于：所述步骤(3)中初粉碎至粒度为70-90目。
9.根据权利要求3所述超微粉益母生化散的制备方法，其特征在于：所述步骤(4)中超微粉碎可以是切式超微粉碎、撞式超微粉碎、磨式超微粉碎、气流粉碎。
10.根据权利要求9所述超微粉益母生化散的制备方法，其特征在于：所述超微粉碎后粒径为15-30μm。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210039273.1A CN114515330A (zh) | 2022-01-13 | 2022-01-13 | 一种超微粉益母生化散及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210039273.1A CN114515330A (zh) | 2022-01-13 | 2022-01-13 | 一种超微粉益母生化散及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114515330A true CN114515330A (zh) | 2022-05-20 |
Family
ID=81597578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210039273.1A Pending CN114515330A (zh) | 2022-01-13 | 2022-01-13 | 一种超微粉益母生化散及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114515330A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107469056A (zh) * | 2017-09-30 | 2017-12-15 | 河南科技学院 | 一种发酵型益母生化散、制备方法及应用 |
| CN108553628A (zh) * | 2018-06-05 | 2018-09-21 | 芮城县维尔富兽药有限公司 | 一种益母生化合剂及其制备方法 |
-
2022
- 2022-01-13 CN CN202210039273.1A patent/CN114515330A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107469056A (zh) * | 2017-09-30 | 2017-12-15 | 河南科技学院 | 一种发酵型益母生化散、制备方法及应用 |
| CN108553628A (zh) * | 2018-06-05 | 2018-09-21 | 芮城县维尔富兽药有限公司 | 一种益母生化合剂及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 钟建新,等: "益母生化散的临床应用效果及毒副作用", 《中兽医医药杂志》 * |
| 陈宝玉,等: "中药超微粉散剂的应用前景", 《今日畜牧兽医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100409891C (zh) | 活血化瘀镇痛止痛纯中药制剂 | |
| CN104799116A (zh) | 一种山羊饲料及其制备方法 | |
| CN114515330A (zh) | 一种超微粉益母生化散及其制备方法 | |
| CN105999105A (zh) | 一种治疗褥疮和糖尿病溃烂的中药组合物及其制备方法 | |
| CN115154514B (zh) | 一种治疗痔疮的中药组合物的工业级制备方法及其产品 | |
| CN103860948B (zh) | 用于治疗气滞热壅证急性乳腺炎的中药及其制备方法 | |
| CN110464755A (zh) | 一种治疗急性肾盂肾炎的中药组合物片剂 | |
| CN104906373A (zh) | 一种治疗心绞痛型冠心病的药物及其制备方法 | |
| CN116350737B (zh) | 一种预防奶牛胎衣不下的组合物及其制备方法 | |
| CN107837315A (zh) | 一种治疗鹅掌风的中药组合物及其制备方法 | |
| CN103656312B (zh) | 一种治疗直肠手术后尿潴留的中药组合物 | |
| CN113577090B (zh) | 牛蒡子苷在制备前列腺增生药物中的应用 | |
| CN107334941A (zh) | 一种治疗慢性盆腔炎的中药及其制备方法 | |
| CN110538251A (zh) | 一种治疗前列腺疾病的中药组合物及其制备方法和应用 | |
| CN105535853A (zh) | 一种临床护理上用于治疗褥疮的中药组合物 | |
| CN106617038A (zh) | 一种改善男性尿频、尿失禁的保健食品组合物及其制备方法和应用 | |
| CN105497320A (zh) | 一种治疗口疮的石膏青黛散 | |
| CN117137977A (zh) | 一种母猪用催奶中药组合物的制备方法 | |
| CN105412706A (zh) | 一种治疗女性内分泌失调的中药组合物 | |
| CN105748932A (zh) | 一种治疗水貂自咬症的中药片剂及其制备方法 | |
| CN116688059A (zh) | 一种治疗痔疮的中药 | |
| CN105853665A (zh) | 一种治疗骨肿瘤的外敷药物及其制备方法 | |
| CN107375554A (zh) | 治疗内分泌失调的药物及其制备方法 | |
| CN110179857A (zh) | 对急性重症胰腺炎合并肝损害的预防及治疗的配方 | |
| CN108159364A (zh) | 一种治疗心内科冠心病的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220520 |